Search clinical trials for: PF-05161704 or Placebo

Total 1150 results

Pfizer

Terminated

A Study to Evaluate the Safety, Tolerability, and Blood Levels of PF-03654746 in Subjects With Mild to Moderate Alzheimer's Disease

Alzheimer's Disease

United States
Pfizer

Withdrawn

A Study Of The Safety, Tolerability, And Pharmacokinetics Of Multiple Doses Of PF-05180999 In Healthy Adults

Migraine
Pfizer

Completed

A Multiple Dose Study Of PF-04620110 In Type 2 Diabetes Patients

Type 2 Diabetes Patients

United States
Pfizer

Completed

Effect of PF-04360365 On ABETA In Patients With Alzheimer's Disease And Healthy Volunteers

Alzheimer's Disease

United States, Sweden
Pfizer

Completed

Safety And Pharmacokinetics Study Of PF-04287881 In Healthy Adults

Respiratory Tract Infections

United States
Pfizer

Completed

A Phase 1 Single-Dose Escalation Study of PF-04308515 in Healthy Volunteers

Healthy Volunteers

United States
Telavant, Inc.
Pfizer

Completed

Evaluation of Safety, Tolerability and Pharmacokinetics of Single Dose of PF-06480605 in Japanese Healthy Participants

Healthy

Japan
Pfizer

Completed

A Study To Assess The Safety Of PF-05335810 In Hypercholesterolemic Subjects

Hypercholesterolemia

United States
Genexine, Inc.

Completed

Safety and Tolerability of GX-P1 in Healthy Male Volunteers

Autoimmune Diseases

Korea, Republic of
Pfizer

Completed

First-In-Human Study Of Single And Multiple Ascending Doses Of PF-06751979

Healthy Subjects

United States
Green Cross Corporation
Korean Center for Disease Control and Prevention

Completed

A Study to Assess Dose-Response, Efficacy (Immunogenicity) and the Safety of GC1109 (GC1109)

Anthrax

Korea, Republic of
Janssen Research & Development, LLC

Completed

A Safety and Tolerability Study of 42037788 (Referred to as CNTO 0007) Compared With Placebo in Patients Who Have Experienced Ischemic Cerebral Infarction (Also Known as Stroke)

Infarction | Ischemia | Stroke

United States
Creabilis SA
Aalborg University Hospital

Completed

A Study to Investigate the Pharmacodynamic Effects of CT327 on Intra-dermal Nerve Growth Factor (NGF) and Evoked Pain Responses, in Healthy Male Volunteers

Neuropathic Pain

Denmark
Pfizer

Completed

A Study of Single Ascending Doses of PF-07258669 in Healthy Adult Participants

Healthy Participants

United States
Biogen

Completed

Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Repeated Doses of PF-04958242 in Healthy Volunteers

Schizophrenia

United States
Biogen

Completed

A Study Of The Effects Of PF-04958242 In Subjects With Age-Related Hearing Loss

Hearing Loss, Sensorineural

United States
Biogen

Completed

A Study To Examine The Safety, Tolerability And Pharmacokinetics Of PF-04958242 In Psychiatrically Stable Subjects With Schizophrenia

Schizophrenia

United States
Pfizer

Completed

A Study To Examine The Safety, Tolerability And Pharmacokinetics Of PF-02545920 In Psychiatrically Stable Subjects With Schizophrenia

Schizophrenia

United States
Pfizer

Completed

First In Human, Single Escalating Oral Dose Study Of PF-06882961 In Healthy Adult Subjects

Healthy Subjects

United States
Pfizer

Terminated

An Outpatient Study Of The Efficacy, Safety, And Tolerability Of PF-02545920 In The Adjunctive Treatment Of Sub-Optimally Controlled Symptoms of Schizophrenia

Schizophrenia

United States
Pfizer

Terminated

A 6-Week Study To Determine The Safety And Effect Of An Investigational Drug On Adults With Type 2 Diabetes Mellitus Taking Metformin

Type 2 Diabetes Mellitus

United States
Pfizer

Completed

A Multiple Oral Doses Study Of PF-06427878 In Healthy Adult Subjects

Healthy Subjects

Belgium
Pfizer

Completed

Study to Evaluate Safety and Tolerability of Single Ascending Doses of Multiple Formulations of PF-06650833 in Healthy Subjects Under Fasted and Fed Conditions

Healthy

United States
Pfizer

Completed

Study to Investigate the Safety, Tolerability, Pharmacokinetics of PF-06305591 in Healthy Male and Female Subjects

Healthy

Belgium
Hanmi Pharmaceutical Company Limited

Completed

Safety and PK of HM10460A (HNK460) in Healthy Adult Japanese and Caucasian Subjects

Healthy

United States
Juventas Therapeutics, Inc.

Completed

Study to Evaluate the Safety and Efficacy of JVS-100 Administered to Adults With Critical Limb Ischemia

Critical Limb Ischemia

United States, India
Samjin Pharmaceutical Co., Ltd.

Completed

Clinical Study to Investigate the Pharmacokinetics and Safety/Tolerability of SA001 in Healthy Male Volunteers

Healthy
Devintec Sagl
Meditrial SrL

Recruiting

Devintec OR-AT0222 Oral Gel for the Treatment of Canker Sores: A Double Blind, Randomized, Placebo Controlled Clinical Investigation

Recurrent Aphthous Ulcer

Italy
Newsoara Biopharma Co., Ltd.

Unknown

Evaluate the Safety, Tolerability and Pharmacokinetics Characteristics of HPP737 in Healthy Volunteers

Healthy

China
Unity Biotechnology, Inc.

Terminated

Long-Term Follow-Up Study of Patients With Osteoarthritis of the Knee Treated With UBX0101 or Placebo

Knee Osteoarthritis

United States
JULIANA AQUINO DE MOURA

Completed

The Effect of Non-hormonal Gel Application in Women in the Menacme With Sexual Dysfunction

Sexual Dysfunction
Akesobio Australia Pty Ltd

Completed

A Study of AK111 in Healthy Subjects

Psoriasis

New Zealand
Curadim Pharma Co., Ltd.

Unknown

A First-in-human Phase 1 Study of CP1050

Healthy Subjects

United Kingdom
GlaxoSmithKline

Completed

First Time in Human Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and the Effect of Food of Single Assending Doses of GSK1482160.

Pain, Inflammatory

United Kingdom
Durham VA Medical Center

Completed

Targeting Cognition in PTSD: Pregnenolone Augmentation of SSRIs

Stress Disorders, Post-Traumatic

United States
Regeneron Pharmaceuticals

Completed

Intravenous/Subcutaneous FIH Study of REGN1154 in Healthy Volunteers

Healthy Volunteers

Australia
Oxagen Ltd

Completed

OC000459 Dose Finding Study in Patients With Mild to Moderate Persistent Asthma

Mild to Moderate Persistent Asthma

Bulgaria, Russian Federation, Hungary, Romania, Ukraine, Poland
Chiesi Farmaceutici S.p.A.

Completed

Safety and Tolerability of Inhaled CHF 6001 in Healthy Volunteers (HV)

Chronic Obstructive Pulmonary Disease (COPD)

United Kingdom
University of Pennsylvania
National Heart, Lung, and Blood Institute (NHLBI)

Completed

Developing Oral LT3 Therapy for Heart Failure - HFrEF (DOT3HF-HFrEF)

Heart Failure With Reduced Ejection Fraction | Low Triiodothyronine Syndrome

United States
Massachusetts General Hospital

Withdrawn

Characterization of the Pharmacodynamic Response to Vaped THC

Vaping | THC
Hanmi Pharmaceutical Company Limited

Unknown

A First-in-human Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of HM15211

Obesity

United States
Pfizer

Completed

First-In-Human Study To Evaluate Safety, Tolerability, And Pharmacokinetics Following Single Ascending And Multiple Ascending Doses of PF-07304814 In Hospitalized Participants With COVID-19.

Viral Disease

United States, Spain, Brazil, Belgium
Pfizer

Completed

Multiple Intravenous Dose Study Of PF-04360365 In Japanese Patients With Mild To Moderate Alzheimer's Disease

Alzheimer's Disease

Japan
Pfizer

Completed

Study To Evaluate The Efficacy And Safety Profile Of PF-06651600 And PF-06700841 In Subjects With Alopecia Areata

Alopecia Areata

United States, Canada, Australia
Pfizer

Completed

A Study Of PF-04171327 In The Treatment Of The Signs And Symptoms Of Rheumatoid Arthritis

Rheumatoid Arthritis

United States, Spain, Czechia, Serbia, Singapore, Taiwan, Hungary, Ukraine, Hong Kong, Korea, Republic of, Russian Federation, Slovakia, Turkey
Telavant, Inc.
Pfizer

Completed

Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Intravenous and Multiple Subcutaneous and Intravenous Doses of PF-06480605 in Healthy Subjects.

Healthy

United States
Pfizer

Completed

A 12-WEEK TITRATE STUDY TO EVALUATE SAFETY, TOLERABILITY AND PHARMACODYNAMICS OF PF-06882961 IN ADULTS WITH TYPE 2 DIABETES MELLITUS AND IN NON-DIABETIC ADULTS WITH OBESITY

Obesity | Diabetes

United States
Pfizer

Completed

A 16 Week Study to Evaluate the Efficacy and Safety of PF-06882961 in Adults With Type 2 Diabetes Mellitus

Diabetes Mellitus, Type 2

United States, Hungary, Taiwan, Bulgaria, Canada, Korea, Republic of, Poland, Slovakia
Pfizer

Completed

A Brief Study To Evaluate The Safety, Tolerability, And Blood Levels Of Multiple Doses Of PF-044467943 Or Placebo In Combination With Donepezil In Subjects With Mild To Moderate Alzheimer's Disease

Alzheimer's Disease

United States
Biogen

Terminated

Study to Evaluate the Safety, Tolerability and Pharmacokinetics of PF-04958242 in Healthy Adult Volunteers

Healthy Volunteers

Singapore

3

Subscribe